ABCL
Price
$2.74
Change
-$0.00 (-0.00%)
Updated
Sep 19 closing price
45 days until earnings call
HUMA
Price
$5.45
Change
-$0.00 (-0.00%)
Updated
Sep 19 closing price
48 days until earnings call
Ad is loading...

ABCL vs HUMA

Header iconABCL vs HUMA Comparison
Open Charts ABCL vs HUMABanner chart's image
AbCellera Biologics
Price$2.74
Change-$0.00 (-0.00%)
Volume$1.47M
CapitalizationN/A
Humacyte
Price$5.45
Change-$0.00 (-0.00%)
Volume$1.56M
CapitalizationN/A
View a ticker or compare two or three
ABCL vs HUMA Comparison Chart
Loading...
ABCL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
HUMA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
ABCL vs. HUMA commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABCL is a Hold and HUMA is a Hold.

COMPARISON
Comparison
Sep 21, 2024
Stock price -- (ABCL: $2.74 vs. HUMA: $5.34)
Brand notoriety: ABCL and HUMA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABCL: 82% vs. HUMA: 55%
Market capitalization -- ABCL: $807.38M vs. HUMA: $620.63M
ABCL [@Biotechnology] is valued at $807.38M. HUMA’s [@Biotechnology] market capitalization is $620.63M. The market cap for tickers in the [@Biotechnology] industry ranges from $595.57B to $0. The average market capitalization across the [@Biotechnology] industry is $2.99B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABCL’s FA Score shows that 0 FA rating(s) are green whileHUMA’s FA Score has 0 green FA rating(s).

  • ABCL’s FA Score: 0 green, 5 red.
  • HUMA’s FA Score: 0 green, 5 red.
According to our system of comparison, ABCL is a better buy in the long-term than HUMA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABCL’s TA Score shows that 3 TA indicator(s) are bullish while HUMA’s TA Score has 5 bullish TA indicator(s).

  • ABCL’s TA Score: 3 bullish, 3 bearish.
  • HUMA’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both ABCL and HUMA are a good buy in the short-term.

Price Growth

ABCL (@Biotechnology) experienced а +2.24% price change this week, while HUMA (@Biotechnology) price change was -6.15% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.40%. For the same industry, the average monthly price growth was +1.46%, and the average quarterly price growth was -0.90%.

Reported Earning Dates

ABCL is expected to report earnings on Nov 05, 2024.

HUMA is expected to report earnings on Nov 07, 2024.

Industries' Descriptions

@Biotechnology (+0.40% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABCL($807M) has a higher market cap than HUMA($621M). HUMA YTD gains are higher at: 88.028 vs. ABCL (-52.014). HUMA has higher annual earnings (EBITDA): -124.91M vs. ABCL (-195.18M). ABCL has more cash in the bank: 670M vs. HUMA (93.6M). HUMA has less debt than ABCL: HUMA (17.9M) vs ABCL (72.1M). ABCL has higher revenues than HUMA: ABCL (33.1M) vs HUMA (0).
ABCLHUMAABCL / HUMA
Capitalization807M621M130%
EBITDA-195.18M-124.91M156%
Gain YTD-52.01488.028-59%
P/E RatioN/AN/A-
Revenue33.1M0-
Total Cash670M93.6M716%
Total Debt72.1M17.9M403%
TECHNICAL ANALYSIS
Technical Analysis
ABCLHUMA
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
73%
Momentum
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
71%
Bearish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 2 days ago
79%
Declines
ODDS (%)
Bearish Trend 15 days ago
87%
Bearish Trend 4 days ago
82%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
74%
View a ticker or compare two or three
Ad is loading...
ABCL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
HUMA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ERBCX18.460.34
+1.88%
Eaton Vance Richard Bernstein Eq Strat C
RLSIX13.610.19
+1.42%
RiverPark Long/Short Opportunity Instl
LDFOX16.100.22
+1.39%
Lord Abbett Fundamental Equity F3
LVOLX21.820.19
+0.88%
SGI US Large Cap Equity A
POGBX48.10N/A
N/A
Putnam Large Cap Growth B

HUMA and

Correlation & Price change

A.I.dvisor indicates that over the last year, HUMA has been loosely correlated with RXRX. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if HUMA jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HUMA
1D Price
Change %
HUMA100%
+2.10%
RXRX - HUMA
49%
Loosely correlated
+2.22%
ABCL - HUMA
42%
Loosely correlated
+0.73%
VIR - HUMA
37%
Loosely correlated
-1.64%
CRSP - HUMA
37%
Loosely correlated
-0.56%
BEAM - HUMA
37%
Loosely correlated
-0.27%
More